Autor segons l'article: Domingo P; Mateo MG; Villarroya J; Cereijo R; Torres F; Domingo JC; Campderrós L; Gallego-Escuredo JM; Gutierrez MDM; Mur I; Corbacho N; Vidal F; Villarroya F; Giralt M
Departament: Medicina i Cirurgia
Autor/s de la URV: Vidal Marsal, Francisco
Paraules clau: Metabolic syndrome Insulin resistance Hals Gdf15 Framingham D:a:d Cardiovascular-disease Cardiovascular risk stress risk prediction profile metabolic syndrome marker lipodystrophy insulin resistance infection hals framingham events dysfunction d cardiovascular risk abacavir a
Resum: Objective: People living with HIV (PLWH) have an increased cardiovascular risk (CVR) owing to dyslipidemia, insulin resistance, metabolic syndrome, and HIV/combination antiretroviral therapy (cART)-associated lipodystrophy (HALS). Atherosclerosis and inflammation are related to growth differentiation factor-15 (GDF15). The relationship between metabolic disturbances, HALS, and CVR with GDF15 in PLWH is not known. Research design and methods: Circulating GDF15 levels in 152 PLWH (with HALS = 60, without HALS = 43, cART-naïve = 49) and 34 healthy controls were assessed in a cross-sectional study. Correlations with lipids, glucose homeostasis, fat distribution, and CVR were explored. Results: PLWH had increased circulating GDF15 levels relative to controls. The increase was the largest in cART-treated PLWH. Age, homeostatic model assessment of insulin resistance 1 (HOMA1-IR), HALS, dyslipidemia, C-reactive protein, and CVR estimated with the Framingham score correlated with GDF15 levels. The GDF15-Framingham correlation was lost after age adjustment. No correlation was found between GDF15 and the D:A:D Data Collection on Adverse Effects of Anti-HIV Drugs (D:A:D) score estimated CVR. CVR independent predictors were patient group (naïve, HALS−, and HALS+) and cumulated protease inhibitor or nucleoside reverse transcriptase inhibitor exposure. Conclusions: PLWH, especially when cART-treated, has increased GDF15 levels—this increase is associated with dyslipidemia, insulin resistance, metabolic syndrome, HALS, and inflammation-related parameters. GDF15 is unassociated with CVR when age-adjusted.
Àrees temàtiques: Medicine, general & internal Medicine (miscellaneous) Medicine (all)
Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
Adreça de correu electrònic de l'autor: francesc.vidal@urv.cat
Identificador de l'autor: 0000-0002-6692-6186
Data d'alta del registre: 2024-09-07
Versió de l'article dipositat: info:eu-repo/semantics/publishedVersion
Enllaç font original: https://www.mdpi.com/2077-0383/11/3/549
URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
Referència a l'article segons font original: Journal Of Clinical Medicine. 11 (3):
Referència de l'ítem segons les normes APA: Domingo P; Mateo MG; Villarroya J; Cereijo R; Torres F; Domingo JC; Campderrós L; Gallego-Escuredo JM; Gutierrez MDM; Mur I; Corbacho N; Vidal F; Vill (2022). Increased Circulating Levels of Growth Differentiation Factor 15 in Association with Metabolic Disorders in People Living with HIV Receiving Combined Antiretroviral Therapy. Journal Of Clinical Medicine, 11(3), -. DOI: 10.3390/jcm11030549
DOI de l'article: 10.3390/jcm11030549
Entitat: Universitat Rovira i Virgili
Any de publicació de la revista: 2022
Tipus de publicació: Journal Publications